vs
Side-by-side financial comparison of Celcuity Inc. (CELC) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Celcuity Inc. is a clinical-stage biotechnology company specializing in oncology. It develops personalized cancer treatment solutions through its proprietary functional cell analysis technology, targeting unmet medical needs for patients with hard-to-treat solid tumors, with primary operations in the U.S. and partnerships across global biopharmaceutical networks.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | — | $265.2M | ||
| Q2 25 | — | $232.1M | ||
| Q1 25 | — | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | — | $191.5M | ||
| Q2 24 | — | $177.2M | ||
| Q1 24 | — | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | — | $-107.8M | ||
| Q2 24 | — | $-102.6M | ||
| Q1 24 | — | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | — | -37.3% | ||
| Q2 25 | — | -45.9% | ||
| Q1 25 | — | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | — | -61.3% | ||
| Q2 24 | — | -56.8% | ||
| Q1 24 | — | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | — | -35.0% | ||
| Q2 25 | — | -43.0% | ||
| Q1 25 | — | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | — | -56.3% | ||
| Q2 24 | — | -57.9% | ||
| Q1 24 | — | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | — | $-0.74 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | — | $-0.88 | ||
| Q2 24 | — | $-0.84 | ||
| Q1 24 | — | $-0.94 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
